Irinotecan Hcl-Trihydraat Accord

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hcl-Trihydraat Accord, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous administration. It is used in the treatment of metastatic colorectal cancer, primarily in adult patients who require systemic chemotherapy.

GNH USA supplies Irinotecan Hcl-Trihydraat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product complies with EU pharmaceutical standards and is manufactured under GMP conditions. It is distributed through a secure cold‑chain logistics network to ensure product integrity during transport.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer.

Metastatic colorectal cancer: improves survival when used in combination chemotherapy regimens. Refractory colorectal cancer: provides an option after progression on first‑line therapies. Colorectal cancer in combination therapy: contributes to tumor response as part of the FOLFIRI regimen.

Irinotecan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea (often delayed) - Neutropenia - Fatigue - Alopecia - Abdominal pain

Serious or Rare Side Effects: - Severe neutropenia or febrile neutropenia - Life‑threatening diarrhea or colitis - Hepatic toxicity (elevated transaminases) - Severe allergic reactions (anaphylaxis) - Pulmonary toxicity (interstitial pneumonitis)

When using Irinotecan, clinicians should observe several safety measures.

Dose adjustment: required in patients with hepatic impairment. Monitoring: regular blood counts to detect neutropenia. Hydration: maintain adequate fluids to reduce risk of severe diarrhea. Drug interactions: avoid concurrent strong CYP3A4 inhibitors. Pregnancy: use only if potential benefit justifies risk; data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase irinotecan exposure. - UGT1A1 inhibitors: can raise active metabolite levels. - Concurrent use with other myelosuppressive agents: risk of severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase bleeding risk. - Diuretics: may affect electrolyte balance. - Radiation therapy: may enhance toxicity.